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RESUMO
Introdução: Neste estudo foram caracterizados e avaliados todos os tumores malignos do pulmão no nosso hospital submetidos a 
termoablação percutânea por radiofrequência guiada por tomografia computadorizada, uma técnica relativamente recente com cres-
cente evidência científica.
Material e Métodos: Os registos clínicos referentes a todas as termoablações percutâneas por radiofrequência realizadas na nossa 
instituição foram retrospectivamente analisados. Realizou-se uma tomografia computadorizada antes e depois de cada procedimento 
para avaliar as características do tumor e, numa segunda fase, para avaliar os resultados e complicações. A recorrência e progressão 
da doença foram determinados através do seguimento imagiológico. A análise Kaplan-Meier foi usada para calcular a sobrevivência. 
A análise univariada identificou os fatores clínicos e patológicos que afetaram a sobrevivência. 
Resultados: Um total de 28 lesões pulmonares malignas, 20 carcinomas primários e oito lesões metastáticas, de 28 doentes (78,6% 
do género masculino, com idade média de 62 ± 17 anos), foram submetidos a termoablação percutânea por radiofrequência entre 
janeiro de 2004 e julho de 2010. Obteve-se necrose total em 74,1% das lesões. Observaram-se complicações imediatas em metade 
dos procedimentos. Das principais complicações, ocorreu a morte em apenas um doente. A sobrevivência mediana global foi de 43,0 
meses para uma média de dois anos de acompanhamento. A sobrevivência mediana sem progressão da doença foi de 31,6 meses. Os 
fatores que mostraram correlação estatisticamente significativa com melhores resultados foram: tamanho da lesão menor que 35 mm, 
doença no estádio III da classificação TNM e realização de tratamentos prévios. A mortalidade por progressão da doença foi de 46,4%.
Discussão: Este procedimento provou ser eficaz no tratamento de lesões pulmonares cancerígenas, com uma baixa incidência de 
complicações graves.
Conclusões: A termoablação percutânea por radiofrequência é um procedimento minimamente invasivo, que aparenta ser vantajoso 
no tratamento de lesões cancerígenas do pulmão.
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ABSTRACT
Introduction: In this study, we reviewed a clinical series composed by all malignant lung lesions submitted to computed tomography-
guided percutaneous thermal radiofrequency ablation, in our hospital, a rather recent technique that has been gaining scientific 
recognition.
Material and Methods: For data purposes, all radiofrequency ablation and corresponding clinical records were retrospectively 
analysed. A computed tomography scan was performed before and after each procedure to evaluate the tumour’s features, and at a 
second step to assess results and complications. The frequency of local recurrence and disease progression were determined based 
on imaging follow-up. Kaplan–Meier analysis was used to estimate survival. Univariate analysis recognized clinical and pathological 
factors affecting survival. These were also tested by multivariate analysis.
Results: A total of 28 malignant lung lesions, 20 primary and 8 metastatic, from 28 patients (78.6% male; mean age 62 ± 17 years old), 
were submitted to computed tomography-guided radiofrequency ablation between January 2004 and July 2010. Total necrosis was 
achieved in 74.1% of the lesions. Immediate radiofrequency ablation-related complications were observed in half of the procedures. 
Among major complications, death occurred in one patient only. Median overall survival was 43.0 months for a mean 2-years follow-up. 
Median progression-free survival was 31.6 months. Lesion’s size smaller than 35 mm, stage III disease by the TNM classification and 
previous treatment attempts were significantly associated with better outcomes. Disease-related mortality was 46.4%.
Discussion: This procedure proved to be efficient to treat lung cancerous lesions, with a low-rate of major complications.
Conclusions: Computed tomography-guided percutaneous radiofrequency ablation is a minimally invasive procedure that appears to 
be valuable in the treatment of lung cancer lesions.
Keywords: Catheter Ablation; Lung Neoplasms; Tomography, X-Ray Computed.
INTRODUCTION
 Lung cancer is the most commonly diagnosed malignant 
disease in the world and has been the primary cause of 
cancer related-death for several decades.1,2 The lung is 
also one of the most likely sites for metastatic malignant 
disease, especially for adenocarcinomas.3
 Established treatment options include surgical 
resection, radiotherapy (RT), chemotherapy (CTX) or a 
combination of these modalities. Although surgery is not 
recommended for advanced disease, in the early-stage 
non-small cell lung cancer (NSCLC), surgical resection is 
still the preferred treatment.4 Unfortunately, not all patients 
are eligible for surgery mostly due to comorbidities, and 
poor cardiorespiratory function in particular, that place 
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may be considered for treatment with conventional external 
beam RT, but this modality poses a considerable risk for 
radiation pneumonitis. Stereotactic RT (SRT) has also been 
increasingly used for the treatment of early-stage lung 
cancer.5,6 However, SRT is also associated with radiation 
pneumonitis and other complications such as rib fractures 
and skin rash, and has been linked with increased lengths 
of hospital stay.7
 Image-guided percutaneous therapies have been 
developed as local or minimally invasive alternative 
treatments, trying to overcome the above referred 
limitations.8,9 Its use in the treatment of diverse solid 
malignancies, specifically hepatic, renal and bone, has 
had successful results and has long been accepted as a 
suitable therapeutic option.10–14 Among these interventional 
radiological procedures, radiofrequency ablation (RFA) is a 
recently developed technique and there is growing scientific 
evidence supporting its use for primary and secondary 
lung tumours treatment.15–24 RFA destroys lung tumours 
via tissue heating, which is attained by the delivery of hot 
thermal energy through percutaneous needles, inserted 
under computed tomography guidance. Immediate cell 
death occurs when tissue temperatures reach more than 
60º C.25 RFA can be performed under conscious sedation 
and the incidence of side effects is quite low. The procedure 
safeness partially depends on the anatomical and 
physiological conditions of the lung itself. A high pulmonary 
vascular flow and constant air exchange promptly dissipate 
heat from normal parenchyma and concentrate energy 
within the tumour, a phenomena known as ‘sink effect’.26,27
 RFA can be associated to other treatment modalities, 
namely RT, offering synergistic results. In fact, compared 
to RT alone, combined therapy has revealed significant 
improvements in local tumour control and survival rates.28,29 
Despite of these advantages and promising results, RFA 
is still not an established technique, since there have 
been very few clinical trials and most oncology units have 
minimum experience of this procedure.
 This study describes our experience in a population 
of patients with malignant lung tumours, mainly primary 
cancers, treated by RFA in a central Portuguese hospital.
MATERIAL AND METHODS
Study Population
 Data from all patients submitted to lung RFA, between 
2004 and 2010, were retrospectively collected. Patients 
with primary or secondary lung cancer were selected to RFA 
after an oncology multidisciplinary board decision. Impaired 
lung function, other comorbidities, anatomical restraints, 
advanced disease and patient refusal to have surgery were 
the main contraindications to surgical treatment as first 
choice (Table 1).
 Before the procedure, a thorough clinical assessment 
was carried out, recent laboratory tests evaluated and 
imaging studies reviewed. Pulmonary function tests were 
not considered mandatory, as there are no constraints 
related to the forced expiratory volume in 1 second 
(FEV1) or the diffusion capacity (DLCO). Antiplatelet and 
anticoagulant medication was previously discontinued. 
Chest CT was the imaging technique chosen to assess 
the lesion’s size, shape, location and their relation to other 
structures, aspects of interest in the preliminary planning.
 All patients provided written informed consent to the 
RFA procedure after a careful explanation of the technique 
and associated risks.
Radiofrequency Technique
 Local anaesthesia with intradermal and subcutaneous 
lidocaine (1%) was used at the needle insertion point 
and conscious sedation was achieved with intravenous 
midazolam and fentanyl. All patients were submitted to a 
pre-anaesthetic consultation and during the procedure were 
continuously monitored by an anaesthesiologist.
 Each patient was specifically positioned over the CT 
table according to the predetermined needle tract, in order 
to provide the shortest and most direct path to the tumour, 
without crossing major thoracic structures. Amendments to 
the needle orientation were made by CT guidance. After the 
final adjustments, an umbrella-tip LeVeen radiofrequency 
(RF) electrode (Boston Scientific, Natick, Massachusetts, 
USA) with sphere diameter between 2 and 4 cm selected as 
appropriated for each lesion, and introduced, deep inside it, 
also under CT guidance (Fig.s 1 and 2).
 The electrode was coupled to a generator RF 3000 
(Boston Scientific) that exhibited temperature, power, 
impedance and time displays and was secured by pads 
placed on the anterolateral aspect of each thigh. Power 
setting was initially 40 W, thereafter being administered in 
a stepwise manner pending a striking rise in impedance, 
which characterizes adequate thermocoagulation, and 
marked the end of the procedure. As criteria for safety 
margins we considered a 6-8 mm normal lung parenchyma 
tissue necrosis.
 Multiplanar reconstructions or maximum intensity 
projections were supplementary obtained when there 
was doubt about sufficient coverage of the tumour by the 
electrodes or to reassess the relationship with neighbouring 
structures.
Post-treatment and Follow-up Studies
 Spiral CT was performed immediately after the ablation 
for a preliminary assessment of results and detection of 
complications (Fig. 2). A high-density area at the treatment 
Table 1 - Reasons for excluding surgery as first treatment approach
  Surgical restraints n (%)
  Comorbidities 9 (32.1)
  Advanced disease 8 (28.6)
  Lung impairment function 6 (21.4)
  Anatomical constraints to surgery 4 (14.3)
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site with a diameter equal to or greater than the initial tumour, 
surrounded by a rim of parenchymal ground-glass, resulting 
of inflammation and oedema induced by the procedure, and 
also non-enhanced after contrast administration was defined 
as successful treatment. All patients had a 2-hours post-
procedure chest radiograph to assess for pneumothorax. 
 Follow-up included clinical examination at the Oncology 
Unit and routine CT scan plus positron emission tomography 
(PET) for 1 year. Frequency of local recurrence, disease 
progression and mortality were the primary end-points.
 Increased enhancement after the intravenous 
administration of contrast material on chest CT at 1-2 
months of follow-up compared to the pre-treatment baseline 
enhancement was recognized as residual or recurrent 
malignant disease. The same principle was considered 
for enduring 18-fludeoxyglucose (18-FDG) on PET uptake 
6 months after ablation. On the other hand, necrosis, 
identified as a non-enhancing area larger than the ablated 
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Figure 1 - Radiofrequency ablation treatment of a lung tumour. 
An umbrella-tip LeVeen RF electrode (Boston Scientific, Natick, 
Massachusetts, USA) is introduced deeply inside the tumour 
lesion, being coupled to a generator RF 3000 (Boston Scientific) 
that presents temperature, power, impedance and time displays.
Figure 2 - Thoracic CT showing images of a nodular lesion diagnosed as a lung adenocarcinoma before radiofrequency ablation (a) and 
at 1, 3, 6 and 12 months of follow-up (b, c, d and e, respectively). 
a b c d e
tumour, cavitation or cysts were considered as complete 
response to treatment.
Statistical Analysis
 Data analysis was done by IBM SPSS Statistics® for 
Windows version 20.0. Follow-up was calculated from the 
date of treatment to the date of last follow-up. The patient 
characteristics and treatment success were reported using 
frequency and descriptive analyses. All analysis related 
to short- and long-term follow-up, including survival, local 
recurrence and disease progression calculations included 
all patients, except the one single case of death procedure-
related. Mortality rates were calculated and the Kaplan–
Meier method applied to estimate survival. Univariate 
analysis (log rank) was carried out to determine the clinical 
and pathological factors affecting survival. The variables 
tested were: age, sex, size and position of the ablated 
lesion, primary tumour histology, Zubrod performance 
status, previous treatments, ablation-related complications, 
local recurrence or disease progression and comorbidities. 
P value of < 0.05 was considered statistically significant. 
Multivariate analysis was performed on all factors (p < 0.10) 
using the Cox proportional hazards regression model. 
RESULTS
Patient Population
 Patient and tumour characteristics are summarized 
in Table 2. A total of 28 patients, 22 men (78.6%), with 
an overall mean (range) age of 62.0 ± 17.0 (6-81) years, 
underwent a single RFA session with only one electrode 
insertion used to treat each one of the lung tumours, 20 
primary cancers (71.4%) and 8 metastatic (28.6%). The 
lesion’s average (range) diameter size was 30.0 ± 13.6 (9-
70) mm and their location was mainly at the lung periphery 
(n = 18; 64.3%). Only 2 patients (7.1%) had not previously 
received any other treatment modality due to low pulmonary 
function, thus RFA being their first therapeutic option. All the 
remaining 26 patients (92.9%) had formerly been submitted 
to combined or isolated cytostatic treatment, 3 of whom also 
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Table 2 - Frequency and Overall Survival by Demographic and Clinical Variables




  Patients, n 27+ 43.0
  Sex NS
    Male 21 (77.8) 97.0
    Female 6 (22.2) 39.7
  Age, yrs NS
    Overall, mean ± SD (range) 69 ± 17 (16-81)
      < 45 3 (11.1) 38.6
     45-60 5 (18.5) 97.0
      > 60 19 (70.4) 31.6
  Zubrod Performance Status* NS
    Zubrod 0 3 (15.0) 31.6
    Zubrod 1 15 (75.0) 97.0
    Zubrod 2 2 (10.0) 14.3
  Tumour Histology NS
    NSCLC 17 (63.0)
    SCLC 3 (11.1)
    Pulmonary Metastasis 7 (25.9)
  Tumour Position NS
    Central 10 (37.0) 43.0
    Peripheral 17 (63.0) 38.6
  Target Lesion Size, mm 0.003
    < 20 7 (25.9) 46.1
    20 - 35 14 (51.9) 43.0
    > 35 6 (22.2) 9.7
  TNM 7th Classification Staging* 0.011
    I 7 (25.0) 39.7
    II 2 (10.0) 10.0
    III 8 (40.0) 97.0
    IV 3 (15.0) 31.6
  Pre-ablation treatments 0.006
    No previous treatment 2 (7.4) 8.9
    Chemotherapy 10 (37.0) 31.6
    Radio-chemotherapy 12 (44.4) 97.0
    Surgery and adjuvant radio-chemotherapy 3 (11.1) 38.6
  Immediate Ablation Outcome NS
    Complete necrosis 20 (74.1) 31.6
    Partial necrosis 4 (14.8) 21.1
    Unsuccessful 3 (11.1) 14.1
  Procedure-related complications NS
    Major 3 (11.1) 7.4
    Minor 11 (40.7) 37.1
    No complication 13 (40.1) 71.6
  Local recurrence NS
    No 24 (88.9) 43.0
    Yes 3 (11.1) 38.6
  Disease progression 0.001
    No 11 (40.7) -
    Yes 16 (59.3) -
  Comorbidities 
    Arterial Hypertension NS
      No 20 (74.1) 97.0
      Yes 7 (25.9) 31.6
    Atrial Fibrillation NS
      No 25 (92.6) 31.6
      Yes 2 (7.4) 10.4
    Ischemic myocardiopathy NS
      No 24 (88.9) 97.0
      Yes 3 (11.1) 43.0
    Diabetes mellitus NS
     No 21 (78.8) 31.6
     Yes 6 (22.2) 39.2
    Dyslipidaemia NS
      No 22 (81.5) 31.6
      Yes 5 (18.5) 24.5
    Respiratory Insufficiency NS
      No 24 (88.9) 31.6
      Yes 3 (11.1) 7.4
    Pulmonary Emphysema NS
      No 21 (78.8) 37.1
      Yes 6 (22.2) 10.4
    Asthma NS
      No 26 (96.3) 31.6
      Yes 1 (3.7) 71.6
Data are presented as n (%) unless otherwise stated. SD: standard deviation. NS: non-significant; + frequency and survival analysis presented at this table exclude the one single case 
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Complications
 Short-term complications were detected in 14 patients 
(50.0%). Eleven patients experienced minor complications 
(39.3%) and 3 patients had major complications (10.7%). 
The most frequent complication was self-limiting 
pneumothorax (25.0%), which occurred in 7 patients. 
Other minor complications included: one case of a small 
self-limited pleural effusion and three cases of mild 
bleeding successfully treated with aminocaproic acid, 
one slight hemoptoic sputum and two intraparenchymal 
haemorrhages. Major complications comprised isolated 
cases of pneumothorax, pleural effusion and subcutaneous 
emphysema that required chest tube drainage for 
complete resolution. Procedure-related mortality occurred 
in one patient three days after the procedure due to 
haemopneumothorax (3.5%) despite immediate chest 
tube insertion. During a one-year follow-up, no long-term 
complications were observed.
Efficacy
 Efficacy treatment analysis excluded the one single case 
of procedure-related mortality. Complete tumour necrosis 
was observed in 20 patients (74.1%). In 4 patients the axial 
diameter did not increase, but there was a ground-glass 
opacity halo and non-enhancement, indicating a 14.8% rate 
of partial response to ablation. Treatment failure, defined as 
absence of all three criteria, occurred in 4 patients (14.8%).
At one-year follow-up, 16 patients (59.3%) had disease 
progression and 3 patients (11.1%) experienced local 
recurrence. Overall mortality during follow-up occurred in 
13 patients (48.1%) and all due to disease progression.
 Overall survival analyses are discriminated in Table 
2. Median overall survival was 43.0 months and median 
progression-free survival was 31.6 months.
 There was no statistically significant difference in 
survival for age, sex, primary tumour histology, tumour 
location, Zubrob performance status and ablation treatment 
success.
 The tumour diameter correlated directly with overall 
survival. When taking into account different categories of 
tumour dimension, overall survival was substantially longer 
for lesions equal to or smaller than 35 mm in diameter 
compared to diameters greater than 35 mm (p = 0.003) by 
an average difference of 32 months.
 TNM staging was associated with statistically significant 
differences in survival (p = 0.011). Median overall survival 
for primary lung cancer was higher for those in stage III, 
97.0 months, and smaller for those in stage II, 10.0 months. 
On the other hand, stages I and IV were associated to 
intermediate survivals, 39.7 months and 31.6 months, 
respectively.
 Ablation-related complications, particularly major ones, 
and previously diagnosed chronic obstructive pulmonary 
disease were associated to lower survival rated but this 
result had no statistical significance.
 Patients with primary lung cancer that had had CTX prior 
to the ablation procedure had a median overall survival of 
89.7 months while those that did not had worst results with 
a survival of 8.6 months (p = 0.003). Pre-procedure CTX, 
with or without other simultaneous treatments, was the 
most important predictor of survival. When associated to 
concomitant radiotherapy, the overall survival increased to 
a median of 97.0 months. Absence of preceding treatments 
had the worst overall survival rates of 8.9 months (p = 0.006). 
Local recurrence had no interference in survival whereas 
disease progression accounted for a meaningful decrease 
in overall survival (p = 0.001). Multivariate analysis showed 
that having been submitted to any kind of previous treatment 
was related to a 4.5-fold increase in overall survival. 
DISCUSSION
 In this study, percutaneous RFA proved to be a minimally 
invasive procedure with confirmed efficacy in the treatment 
of isolated lung cancerous lesions, either primary or 
secondary, tumour lung lesions in highly selected patients. 
It is a feasible alternative either when surgery is not possible 
or is refused, and as a complementary role in treatment for 
lung cancer.
 Imaging follow-up is vital to certificate treatment success 
and exclude the presence of residual tumour after ablation. 
Contrast-enhanced CT scan appeared to be a reliable 
way to immediately evaluate treatment results and certify 
complete tumour necrosis by measuring the post-treatment 
size increase at the tumour site, recognizing ground-glass 
opacity halo and discarding enhancement after contrast 
administration. All three criteria were identified in 21 
patients, which were consistent with complete necrosis and 
correlated to a success treatment rate of 75.0%. Possible 
explanations for the 25.0% rate of incomplete necrosis and 
treatment failure are some degree of pre-existing tumour 
necrosis and raised heat ‘sink effect’, both associated to 
higher energy requirements,30 and inaccurate electrode 
placement. In one case, it was not possible to assess 
immediate treatment response due to major complications 
that led to the patient’s death.
 In the current study, there was a low rate of local 
recurrence, which corroborates the ablation high 
effectiveness. However, mean (range) follow-up during 
24.0 ± 20.7 months only, may have induced a slight 
underestimation, since it has been stated that residual 
tumour may recur up to 2 years after RFA.
 Overall procedure-related complications incidence 
(55.2%) was significantly higher than that reported in 
previous studies31 although the overwhelming majority were 
mild and self-limited, and the severe ones led to only one 
fatal outcome. Procedure-related complications showed 
no correlation with overall survival in univariate analysis. 
This excessive rate of complications might be interrelated 
to a high prevalence of pulmonary comorbidities, such as 
asthma, COPD and emphysema. In fact, the patient who 
died from the procedure had severe airway obstruction due 
to extensive centrilobular and bullous emphysema, which 
may call into question if pulmonary function is not after all 











68Revista Científica da Ordem dos Médicos          www.actamedicaportuguesa.com                                                                                                                
Tavares e Castro A, et al. Radiofrequency thermal ablation in lung cancer, Acta Med Port 2015 Jan-Feb;28(1):63-69
procedure. Also, in almost half of those that experienced 
complications (43.8%) there was no anatomical cleavage 
plane with some important structures such as the pleura, 
blood vessels and the thoracic wall.
 Disease stages, according to TNM Classification of 
primary malignant lung cancer (7th edition), correlated 
meaningfully with overall survival (p = 0.011). Stage 
III was associated with the best overall survival while 
stage IV presented intermediate results, suggesting that 
radiofrequency ablation may be effectively executed in 
patients with advance disease. However, the overall small 
sample size and the low number of patients in some of the 
disease stages limit this conclusion.
 The lack of association between the lesion location and 
its histological type indicates that RFA may be employed 
in several types of central or peripheral lung tumours with 
similar results. 
 Consistent with previous reports, one important 
prognostic factor was the target lesion axial diameter, 
with superior overall survival for tumours smaller than 35 
mm, although some studies report successful treatment in 
tumours up to 50 mm.24,32
 There were longer overall survival rates among patients 
who underwent former systemic CTX, radio-CTX or surgery 
and adjuvant radio-CTX, indicating that RFA may be 
promisingly coupled with other treatment modalities, even 
lung resection. Only 5 of these patients had advanced 
disease. Concurrently, the mean lesion’s diameter was less 
than 30 mm, which may help explain the survival rates. Only 
2 patients had no other kind of treatment prior to the ablation 
procedure, and both had lower overall survival rates. These 
patients presented particularly large primary lung tumour 
lesions with 40 and 70 mm in axial diameter respectively 
(average 55 mm), when compared to the average 30 mm 
diameter in the by-other modalities treated group and as 
previously reported, size is thus a major feature affecting 
survival. However, these preliminary conclusions are still 
waiting for future validation in prospective trials.
 In the follow-up analysis, disease progression occurred 
in more than half of the patients, being the cause of death 
in all the 13 deceased patients, corresponding to a disease-
related mortality of 46.4%. However, local recurrence 
occurred in only 2 patients, which suggests that RFA may 
be a highly effective procedure in controlling lung tumour 
growth and providing its successful destruction.
 Our study has several limitations. The first is the 
small sample size, which constraint the strength of our 
conclusions. The second, and probably the most important 
limitation worth noting, is that our study population is 
highly heterogeneous. In fact, we included patients with 
different histological primary and secondary tumours, 
including adenocarcinoma, squamous cell carcinoma and 
neuroendocrine cancer, and also patients submitted to 
diverse treatment schemes and modalities. However, most 
of the studies previously published have also dealt with 
heterogeneous and small populations.18,20,21,28,33 The most 
obvious explanation for this is that RFA is still not a fully 
implemented treatment for lung cancer, making it difficult to 
enrol in a study a significant number of patients with similar 
characteristics. In addition, the most important criteria for 
RFA is contraindication for surgery, which encompasses a 
vast group of patients. Nonetheless, assembling a series 
of patients submitted to distinct treatment modalities 
allowed us to observe that RFA combined with other 
treatment modalities may have an excellent synergistic 
effect, improving lung tumours outcomes, especially in 
patients unfit for surgery or that refuse surgical treatment. 
Furthermore, it may be used to treat recurrent lesions after 
an early surgical approach, even more so when we consider 
that repeated lung surgeries pose significant procedure-
related morbidity and modest results.23 
 As for the strengths of our study, it is to stress the fact 
of assembling so much clinical data for each patient, the 
long-term 2-year follow-up when compared to shorter-term 
reports and the meticulous multivariate analysis that was 
performed, testing the main variables affecting survival.
CONCLUSION
 In this study, CT-guided percutaneous RFA is a 
minimally invasive procedure, associated to low morbidity 
and mortality rates and proven efficacy in the treatment of 
primary or metastatic small tumour lung lesions, especially 
when combined with other lung cancer treatment modalities. 
Advantages of RFA include the possibility of performing 
multiple sessions, even in patients with limited pulmonary 
reserve, as well as repeating the treatment with a relatively 
low risk of complications. However, further studies are 
needed to empower our findings, specifically studies with 
large sample sizes.
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